157 related articles for article (PubMed ID: 31412122)
1. Sensitivity of Human Papillomavirus (HPV) Lineage and Sublineage Variant Pseudoviruses to Neutralization by Nonavalent Vaccine Antibodies.
Godi A; Kemp TJ; Pinto LA; Beddows S
J Infect Dis; 2019 Nov; 220(12):1940-1945. PubMed ID: 31412122
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S
J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963
[TBL] [Abstract][Full Text] [Related]
3. Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine.
Godi A; Bissett SL; Miller E; Beddows S
PLoS One; 2015; 10(10):e0140926. PubMed ID: 26495976
[TBL] [Abstract][Full Text] [Related]
4. Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines.
Ahmed AI; Bissett SL; Beddows S
Infect Genet Evol; 2013 Aug; 18():151-9. PubMed ID: 23722024
[TBL] [Abstract][Full Text] [Related]
5. Impact of naturally occurring variation in the human papillomavirus 52 capsid proteins on recognition by type-specific neutralising antibodies.
Godi A; Bissett SL; Masloh S; Fleury M; Li S; Zhao Q; Xia N; Cocuzza CE; Beddows S
J Gen Virol; 2019 Feb; 100(2):237-245. PubMed ID: 30657447
[TBL] [Abstract][Full Text] [Related]
6. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
[TBL] [Abstract][Full Text] [Related]
7. Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine.
Godi A; Panwar K; Haque M; Cocuzza CE; Andrews N; Southern J; Turner P; Miller E; Beddows S
Vaccine; 2019 Apr; 37(18):2455-2462. PubMed ID: 30926298
[TBL] [Abstract][Full Text] [Related]
8. Impact of Naturally Occurring Variation in the Human Papillomavirus 58 Capsid Proteins on Recognition by Type-Specific Neutralizing Antibodies.
Godi A; Martinelli M; Haque M; Li S; Zhao Q; Xia N; Cocuzza CE; Beddows S
J Infect Dis; 2018 Oct; 218(10):1611-1621. PubMed ID: 29905865
[TBL] [Abstract][Full Text] [Related]
9. Development of a Triple-Color Pseudovirion-Based Assay to Detect Neutralizing Antibodies against Human Papillomavirus.
Nie J; Liu Y; Huang W; Wang Y
Viruses; 2016 Apr; 8(4):107. PubMed ID: 27120611
[TBL] [Abstract][Full Text] [Related]
10. Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities.
Bissett SL; Draper E; Myers RE; Godi A; Beddows S
Vaccine; 2014 Feb; 32(10):1139-46. PubMed ID: 24440205
[TBL] [Abstract][Full Text] [Related]
11. Impact of naturally occurring variation in the human papillomavirus (HPV) 33 capsid proteins on recognition by vaccine-induced cross-neutralizing antibodies.
Godi A; Bissett SL; Miller E; Beddows S
J Gen Virol; 2017 Jul; 98(7):1755-1761. PubMed ID: 28691664
[TBL] [Abstract][Full Text] [Related]
12. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.
Pastrana DV; Buck CB; Pang YY; Thompson CD; Castle PE; FitzGerald PC; Krüger Kjaer S; Lowy DR; Schiller JT
Virology; 2004 Apr; 321(2):205-16. PubMed ID: 15051381
[TBL] [Abstract][Full Text] [Related]
13. Naturally Occurring Major and Minor Capsid Protein Variants of Human Papillomavirus 45 (HPV45): Differential Recognition by Cross-Neutralizing Antibodies Generated by HPV Vaccines.
Godi A; Facchetti A; Bissett SL; Cocuzza C; Miller E; Beddows S
J Virol; 2015 Dec; 90(6):3247-52. PubMed ID: 26719255
[TBL] [Abstract][Full Text] [Related]
14. Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial.
Safaeian M; Kemp TJ; Pan DY; Porras C; Rodriguez AC; Schiffman M; Cortes B; Katki H; Wacholder S; Schiller JT; Gonzalez P; Penrose K; Lowy DR; Quint W; van Doorn LJ; Herrero R; Hildesheim A; Pinto LA
Hum Vaccin Immunother; 2013 Jul; 9(7):1399-406. PubMed ID: 23571174
[TBL] [Abstract][Full Text] [Related]
15. Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.
Bissett SL; Godi A; Fleury MJ; Touze A; Cocuzza C; Beddows S
J Virol; 2015 Aug; 89(15):7748-57. PubMed ID: 25995264
[TBL] [Abstract][Full Text] [Related]
16. Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: A systematic review and meta-analysis.
Bissett SL; Godi A; Jit M; Beddows S
Vaccine; 2017 Jul; 35(32):3922-3929. PubMed ID: 28633892
[TBL] [Abstract][Full Text] [Related]
17. Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2.
Seitz H; Schmitt M; Böhmer G; Kopp-Schneider A; Müller M
Int J Cancer; 2013 Feb; 132(3):E139-48. PubMed ID: 22961598
[TBL] [Abstract][Full Text] [Related]
18. Genetic diversity of human papillomavirus types 35, 45 and 58 in cervical cancer in Brazil.
Basto DL; Vidal JP; Pontes VB; Felix SP; Pinto LC; Soares BM; Martins LF; Correa FM; Montenegro RC; Chaves CBP; Almeida LM; Moreira MÂM
Arch Virol; 2017 Sep; 162(9):2855-2860. PubMed ID: 28597068
[TBL] [Abstract][Full Text] [Related]
19. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection.
Kemp TJ; Hildesheim A; Safaeian M; Dauner JG; Pan Y; Porras C; Schiller JT; Lowy DR; Herrero R; Pinto LA
Vaccine; 2011 Mar; 29(11):2011-4. PubMed ID: 21241731
[TBL] [Abstract][Full Text] [Related]
20. Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins.
Bissett SL; Mattiuzzo G; Draper E; Godi A; Wilkinson DE; Minor P; Page M; Beddows S
Vaccine; 2014 Nov; 32(48):6548-55. PubMed ID: 25203446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
